← boardnext 2027-03-31
HURA
TuHURA Biosciences, Inc.distress 9/10 · high distress / dilution risk$2.240%today-31% from 52w high
Oncology 1
Lead: Merkel Cell Carcinoma · target PD-1
Revenue
pre-revenue
Liquidity
$6M
Runway
0.2 yrs
Shares 1y
+27%
Price & events
+229.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.9%
1W
-15.2%
1M
-2.2%
3M
+235.3%
6M
-24.1%
1Y
-71.2%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $142.65M
- Volume
- 4.06K
- 52 Week Range
- $0.44 – $3.25
- Total Shares
- 63.68M
- Float Shares
- 39.66M
- Short %
- 14.20%
- % Held by Insiders
- 34.65%
- % Held by Institutions
- 14.99%
- RVOL
- 0.01x
Pipeline stages · 1 programs
IFx-Hu2.0, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-31 Estimated 50% readout ~2027-06-14 | Phase 2/3 | IFx-Hu2.0, Pembrolizumaborphan | Advanced Or Metastatic Merkel Cell Carcinoma | — | recruiting |
| 2026-05-31 | Phase 1 | IFx-Hu2.0, Pembrolizumaborphan | Advanced Or Metastatic Merkel Cell Carcinoma | 9 | recruiting |
Catalyst news & presentations · 17
- 2H 2027Guided 55%readoutPhase 3IFx-2.0 · Topline results from Phase 3 accelerated approval trialSEC 8-K
- 2H 2027Guided 55%enrollment completesecondaryPhase 3IFx-2.0 · Complete enrollment in Phase 3 study as adjunctive therapy to KeytrudaSEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryPhase 1/2TBS-2025 · Initiate Phase 1b/2 trial of VISTA inhibitorSEC 8-K
- 2H 2026Guided 55%conferencedata presentationsecondaryPhase 3IFx-2.0 · Present data at scientific conferenceSEC 8-K
- 2H 2026Guided 55%conferencedata presentationsecondaryMDSC Inhibitors (bi-specific ADCs) · Presentations at key scientific meetingsSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 1H 2026regulatory submissionFiled (NDA/BLA)TBS-2025 · Planned FDA IND meeting to discuss Phase 1b/2 development planSEC 8-K
- 1H 2026trial initiationsecondaryMDSC Inhibitors (bi-specific ADCs) · Select lead ADC for proof-of-concept study in AMLSEC 8-K
- 2026-04-21partnershipEntered into $50 million revolving credit facility with Parkview Holdings One LLC, an affiliate of largest stockholder.SEC 8-K
- on or before December 31, 2025enrollment completesecondaryREM-001 · Enroll at least 10 cutaneous metastatic breast cancer patients in a dose-response study of REM-001 and complete 8-week follow-upSEC 8-K
- 2nd Half 2025trial initiationsecondaryPhase 2TBS-2025 · Phase 2 trial of TBS-2025 in combination with menin inhibitor in NPM1 mutated AMLSEC 8-K
- 2025-06-30partnershipTBS-2025 · Acquired Kineta, Inc., including VISTA-inhibiting monoclonal antibody TBS-2025SEC 8-K
- second quarter 2025trial initiationsecondaryPhase 3IFx-2.0 · registrational Phase 3 clinical trial planned to beginSEC 8-K
- 14 – 18 months from initiation (June 2025)enrollment completesecondaryPhase 3IFx-2.0 · Last patient enrolled in Phase 3 trial for first-line advanced/metastatic Merkel cell carcinomaSEC 8-K
- 2024-12-11partnershipTuHURA entered into a merger agreement with KinetaSEC 8-K
- 2024-10-18partnershipCompleted merger with TuHURA, resulting in name change to TuHURA BiosciencesSEC 8-K
- 2024-01-24clinical holdIFx-2.0 · FDA placed partial clinical hold on planned Phase 3 trial of IFx-2.0SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+259% upside) · 5 analysts
- 2026-04-27CitizensMarket Outperform
- 2026-02-03HC Wainwright & Co.Buy
- 2026-01-09HC Wainwright & Co.Buy
- 2025-11-14Maxim GroupBuy
- 2025-05-16HC Wainwright & Co.Buy
- 2025-04-03HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-16The Inbox Can Wait, HURA Party Returns on August 26 - media-marketing.com
- 2026-07-14(HURA) Technical Pivots with Risk Controls (HURA:CA) - Stock Traders Daily
- 2026-06-29TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-28TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 2000 Growth Benchmark - marketscreener.com
- 2026-06-22TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, No Revenue Yet, Stock Rises on Pipeline Progress - dars.gov.et
- 2026-06-18‘There Is a Lot of Rich Detail in Everyday Life’: Sohrab Hura Captures a Lesser-Seen Kashmir - Ocula
- 2026-06-15New antibody to test in specific leukemia mutations as TuHURA files with FDA - Stock Titan
- 2026-06-15TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.